| Relevance of the COBRA trial in current psoriasis practice. | |
| | |
MedLine Citation:
|
PMID: 18154218 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The goal of psoriasis therapy is shifting from an emphasis on the short-term management of severe outbreaks to the maintenance of continuous long-term control. Topical corticosteroids play an important role in all of the therapeutic strategies used. The Clobex Spray Community-Based Research Assessment (COBRA) trial involved 455 community dermatologists throughout the United States who participated in a multicenter, 4-week, open-label, observational, community-based trial of twice-daily clobetasol propionate spray 0.05% as monotherapy or as an addition to a treatment regimen present at the time of study entry. Dermatologists were allowed to select study participants based on their own professional judgment, which resulted in the largest number of study participants ever enrolled in a psoriasis community-based trial, with 2488 subjects enrolled from 455 investigational sites. Of the total population, 1254 subjects with moderate to severe plaque psoriasis treated with clobetasol propionate spray 0.05% twice daily as monotherapy and 731 subjects treated with clobetasol propionate spray 0.05% twice daily in addition to an existing regimen were evaluated for efficacy with at least one follow-up visit. Data from this trial suggest that superpotent topical corticosteroids are appropriate for use as monotherapy and when added to existing therapeutic regimens. The effectiveness and tolerability results from this study suggest that clobetasol propionate spray 0.05% is a potent, well-tolerated, and versatile topical therapy for moderate to severe plaque psoriasis that may be used in a diverse range of settings to help dermatologists optimize response to therapy. |
| | |
Authors:
|
John Y M Koo |
Related Documents
:
|
17975448 - Computer-aided therapy in aphasia therapy: evaluation of assignment criteria. 7604468 - Ciprofloxacin-induced acute psychosis. 8604468 - Thoracobiliary fistula. 1225978 - Initiation problems and time structuring in brief sex therapy. 12753938 - The general form of 0-1 programming problem based on dna computing. 911378 - Appointment-keeping behavior re-evaluated. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cutis; cutaneous medicine for the practitioner Volume: 80 ISSN: 0011-4162 ISO Abbreviation: Cutis Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-12-24 Completed Date: 2008-01-10 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0006440 Medline TA: Cutis Country: United States |
Other Details:
|
Languages: eng Pagination: 4-11 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, University of California San Francisco Medical Center, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Adult Aged Clobetasol / administration & dosage*, adverse effects Drug Therapy, Combination Female Glucocorticoids / administration & dosage*, adverse effects Humans Male Middle Aged Patient Satisfaction Psoriasis / drug therapy*, pathology Quality of Life Severity of Illness Index Skin / pathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Glucocorticoids; 25122-41-2/Clobetasol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Im...
Next Document: Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial.